Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
Type:
Grant
Filed:
December 7, 2011
Date of Patent:
November 25, 2014
Assignee:
Affitech Research AS
Inventors:
Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
Type:
Grant
Filed:
December 11, 2012
Date of Patent:
October 14, 2014
Assignee:
MedImmune Limited
Inventors:
Susan Ann Cartlidge, Jianying Dong, Mark Hickinson, Ian Foltz, Jaspal Singh Kang
Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.
Abstract: Provided are antigenic determinants of human death receptor DR5. The antigenic determinants have the amino acid sequence of LITQQDLAPQQRA (SEQ ID No. 7), wherein the core polypeptide is QDLAP (SEQ ID No. 1). The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine.
Type:
Grant
Filed:
April 3, 2009
Date of Patent:
July 29, 2014
Assignee:
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
July 29, 2014
Assignee:
ImmunoGen, Inc.
Inventors:
Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
Abstract: The present invention is directed to compositions and methods for treating immune system mediated disease. In particular, certain embodiments of the present invention use BH3 mimetic therapy as an efficacious treatment of the effector phase of RA wherein the compositions and methods of the present invention markedly reduce the level of the Bcl-2 antagonist protein Bim present in RA synovial tissue as compared to control patients. Therefore, the present invention involves restoring the function of Bim in order to ameliorate inflammatory arthritis. In connection therewith, systemic delivery of a peptide to the BH3 domain of Bim effectively inhibits the development of K/B×N serum transfer-induced arthritis which closely resembles the effector phase of RA.
Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
June 24, 2014
Assignee:
Industrial Technology Research Institute
Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.
Type:
Grant
Filed:
November 2, 2009
Date of Patent:
June 10, 2014
Assignee:
Green Cross Corporation
Inventors:
Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
Type:
Grant
Filed:
September 17, 2012
Date of Patent:
May 6, 2014
Assignee:
The UAB Research Foundation
Inventors:
Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
Abstract: The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.
Type:
Grant
Filed:
November 6, 2009
Date of Patent:
April 1, 2014
Assignee:
Wayne State University
Inventors:
Wei-Zen Wei, Gen Sheng Wu, Marie P. Piechocki, Richard F. Jones
Abstract: The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
Type:
Grant
Filed:
August 27, 2009
Date of Patent:
March 4, 2014
Assignee:
Symphogen A/S
Inventors:
Mikkel Wandahl Pedersen, Michael Kragh, Adam S. Hey, Helle Jacobsen
Abstract: The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR.
Type:
Grant
Filed:
October 28, 2010
Date of Patent:
February 25, 2014
Assignee:
AbbVie Biotherapeutics Inc.
Inventors:
Robert B. Dubridge, David B. Powers, Charles M. Forsyth
Abstract: The present application relates to a method for treating or preventing Th17 inflammatory disease mediated with IL-6 or IL-17 by administration of medication which inhibits vascular endothelial growth factor receptors, and a pharmaceutical composition therefor.
Type:
Grant
Filed:
May 20, 2010
Date of Patent:
February 18, 2014
Assignee:
Postech Academy-Industry Foundation
Inventors:
Yoon Keun Kim, Yong Song Gho, Yu Sun Kim
Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
Type:
Grant
Filed:
October 5, 2009
Date of Patent:
January 21, 2014
Assignee:
Genentech, Inc.
Inventors:
Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang
Abstract: The present invention provides antibodies that bind human TGF-alpha and human Epiregulin and are characterized as having high affinity, selective, and strong neutralizing properties. The antibodies are useful in the treatment of diabetic nephropathy.
Type:
Grant
Filed:
March 28, 2012
Date of Patent:
December 24, 2013
Assignee:
Eli Lilly and Company
Inventors:
Catherine Brautigam Beidler, Josef George Heuer, Ramona Judita Petrovan
Abstract: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or ?2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or ?2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or ?2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.
Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
Abstract: This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided.
Type:
Grant
Filed:
September 30, 2011
Date of Patent:
September 10, 2013
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
Type:
Grant
Filed:
August 19, 2011
Date of Patent:
September 3, 2013
Assignee:
Biogen Idec MA Inc.
Inventors:
Christine M. Ambrose, Jeffrey S. Thompson